ArticleJAACAP open2026
Treatment Patterns and Clinical Outcomes in Youth With Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.
Article in JAACAP open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The co-occurrence of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) is common and associated with greater clinical complexity. This study evaluated real-world treatment patterns and outcomes among children and adolescents with ADHD, comparing those with and without comorbid ASD. Method: A retrospective comparative cohort study analyzed electronic health records from the TriNetX Research Network, including 869,510 children and adolescents aged 3 to 18 years with ADHD, of whom 155,543 (17.9%) had ASD. Outcomes included treatment patterns and clinical outcomes. Analyses used propensity score matching and Cox proportional hazards models adjusted for sociodemographic and psychiatric factors, estimating relative risks (RRs), hazard ratios (HRs), and 95% confidence intervals over 1 year. Results: Children and adolescents with ADHD+ASD had higher psychiatric comorbidity and health care use than those without ASD. They received fewer CNS stimulant prescriptions (RR = 0.82, 95% CI = 0.81-0.83) but a higher proportion of non-stimulant prescriptions (RR = 1.52, 95% CI = 1.50-1.54) compared with those without ASD. Slightly higher ADHD prescribing occurred among Hispanic youth (RR = 1.03) and preschoolers (RR = 1.23) with ASD compared to those without ASD. Within the ADHD+ASD cohort, CNS stimulants were associated with the most favorable outcomes, including reduced hospitalization, emergency visits, suicidal behaviors, and subsequent antipsychotic/mood stabilizer initiation (adjusted HRs 0.33-0.83). Atomoxetine showed relatively favorable outcomes among non-stimulants. Conclusion: Comorbid ASD in children and adolescents with ADHD increases clinical burden and shifts treatment from CNS stimulants to non-stimulants and other psychotropics. Despite lower use, CNS stimulants are associated with improved outcomes, underscoring the need for prospective studies examining the risk-to-benefit ratio in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.